Related Experiment Video
Updated: Sep 3, 2025
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia
Guy Khalaf1, Claudia Mattern2, Mélina Begou3
1U1195 Diseases and Hormones of the Nervous System, INSERM and Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France.
Abstract:
Pelizaeus-Merzbacher Disease (PMD) is an inherited leukodystrophy affecting the central nervous system (CNS)-a rare disorder that especially concerns males. Its estimated prevalence is 1.45-1.9 per 100,000 individuals in the general population. Patients affected by PMD exhibit a drastic reduction or absence of myelin sheaths in the white matter areas of the CNS. The Proteolipid Protein 1 (PLP1) gene encodes a transmembrane proteolipid protein. PLP1 is the major protein of myelin, and it plays a key role in the compaction, stabilization, and maintenance of myelin sheaths. Its function is predominant in oligodendrocyte development and axonal survival. Mutations in the PLP1 gene cause the development of a wide continuum spectrum of leukopathies from the most severe form of PMD for whom patients exhibit severe CNS hypomyelination to the relatively mild late-onset type 2 spastic paraplegia, leading to the concept of PLP1-related disorders. The genetic diversity and the biochemical complexity, along with other aspects of PMD, are discussed to reveal the obstacles that hinder the development of treatments. This review aims to provide a clinical and mechanistic overview of this spectrum of rare diseases.
Insights
Pelizaeus-Merzbacher Disease (PMD) is a rare inherited CNS disorder affecting males, characterized by myelin sheath absence. Mutations in the PLP1 gene cause a spectrum of leukopathies, hindering effective treatment development.
Area of Science:
- Neuroscience
- Genetics
- Rare Diseases
Background:
- Pelizaeus-Merzbacher Disease (PMD) is an inherited leukodystrophy impacting the central nervous system (CNS), primarily affecting males.
- It is characterized by a significant reduction or absence of myelin sheaths in CNS white matter.
- The estimated prevalence is 1.45-1.9 per 100,000 individuals.
Purpose of the Study:
- To provide a clinical and mechanistic overview of Pelizaeus-Merzbacher Disease (PMD) and related disorders.
- To discuss the genetic diversity and biochemical complexity of PMD.
- To highlight obstacles hindering the development of effective treatments for this rare disease spectrum.
Main Methods:
- This review synthesizes existing clinical and research data on PMD.
- It examines the role of the Proteolipid Protein 1 (PLP1) gene and its mutations.
- The review discusses the spectrum of leukopathies associated with PLP1 gene variations.
Main Results:
- Mutations in the PLP1 gene are responsible for a range of leukopathies, from severe PMD to milder forms like spastic paraplegia type 2.
- PLP1 protein is crucial for myelin sheath compaction, stabilization, and maintenance, as well as oligodendrocyte development and axonal survival.
- The genetic and biochemical complexity of PMD presents significant challenges for therapeutic development.
Conclusions:
- PLP1-related disorders represent a spectrum of CNS leukopathies caused by mutations in the PLP1 gene.
- Understanding the genetic and mechanistic basis of PMD is essential for advancing treatment strategies.
- Further research is needed to overcome the current obstacles in developing therapies for these rare neurological conditions.
Related Concept Videos
01:22Lysosomal Hydrolases
01:21Satellite Stem Cells and Muscular Dystrophy
01:33Pleiotropy
01:43Sex-linked Disorders